C12N 2501/405
Cell cycle regulated proteins
Official title: Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
C12N2501/405 (Cell cycle regulated proteins) appears on 48 US grants and 104 published applications in this corpus.
Search patents in C12N- Granted patents
- 48
- Published applications
- 104
- Assignees
- 68
- Inventors
- 212
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 3 |
| 2004 | 0 | 2 |
| 2005 | 0 | 2 |
| 2006 | 0 | 3 |
| 2007 | 0 | 3 |
| 2008 | 1 | 0 |
| 2009 | 0 | 6 |
| 2010 | 0 | 3 |
| 2011 | 3 | 4 |
| 2012 | 2 | 4 |
| 2013 | 1 | 7 |
| 2014 | 3 | 5 |
| 2015 | 1 | 8 |
| 2016 | 9 | 3 |
| 2017 | 5 | 6 |
| 2018 | 4 | 5 |
| 2019 | 4 | 6 |
| 2020 | 2 | 5 |
| 2021 | 2 | 4 |
| 2022 | 2 | 4 |
| 2023 | 3 | 7 |
| 2024 | 1 | 5 |
| 2025 | 1 | 4 |
| 2026 | 4 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for generating oligodendrocyte progenitor cells8 Sep 2026US 12,729,368 B2Trailhead Biosystems Inc.
- Immune cell function17 Feb 2026US 12,551,530 B2Kite Pharma, Inc.
- Application of TGF-B inhibitor in inducing neural stem cells and organoid formation10 Feb 2026US 12,545,892 B2Iregene Therapeutics Ltd
- P21 expressing monocytes for cancer cell therapy6 Jan 2026US 12,514,902 B2Institut Gustave Roussy
- Nucleoside modified mRNA and uses thereof29 Jul 2025US 12,371,666 B2Boston Medical Center Corporation
- Universal cell and preparation method therefor30 Jul 2026US 2026/0218129 A1Xellsmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
- Age-modulating compounds and methods for making age-modulated cells7 May 2026US 2026/0125647 A1Memorial Hospital for Cancer and Allied Diseases
- P21 Expressing Monocytes for Cancer Cell Therapy5 Mar 2026US 2026/0061029 A1Institut Gustave Roussy
- Culture medium suitable for the differentiation and culture of intestinal organoids1 Jan 2026US 2026/0002131 A1Friedrich Miescher Institute for Biomedical Research
- Nucleoside modified mrna and uses thereof9 Oct 2025US 2025/0313806 A1Boston Medical Center Corporation
Most cited
By later US patents
- Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors121US 8,187,878 B2University of Georgia Research Foundation, Inc. · 2012
- PDX1-expressing dorsal and ventral foregut endoderm19US 9,499,795 B2ViaCyte, Inc. · 2016
- Transgenic mouse defective in WW45 function and use in screening compounds for anti-tunour activity4US 8,076,532 B2Korea Advanced Institute of Science and Technology · 2011
- Expanding hematopoietic stem cells4US 8,741,640 B22014
- Differentiation of human pluripotent stem cells4US 9,234,178 B2Janssen Biotech, Inc. · 2016